Dexcom

Dexcom

Develops continuous glucose monitoring systems

About Dexcom

Simplify's Rating
Why Dexcom is rated
B
Rated B on Competitive Edge
Rated A on Growth Potential
Rated C on Rating Differentiation

Industries

Data & Analytics

Healthcare

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

1999

Overview

Company Does Not Provide H1B Sponsorship

Dexcom develops and sells continuous glucose monitoring (CGM) systems designed to help individuals manage diabetes. The main product, the Dexcom G6 CGM System, provides users with real-time glucose readings, enabling better management of their condition. The system consists of a small sensor placed under the skin that continuously measures glucose levels and sends the data to a smartphone or receiver. This allows users to monitor their glucose levels throughout the day without the need for fingerstick tests. Dexcom differentiates itself from competitors by offering a user-friendly interface and advanced data analytics through its Dexcom CLARITY software, which helps users and healthcare providers make informed decisions based on glucose trends. The company's goal is to enhance the quality of life for diabetes patients by providing accurate and accessible glucose monitoring solutions.

Simplify Jobs

Simplify's Take

What believers are saying

  • The wearable health tech market is projected to grow at a 15.9% CAGR until 2030.
  • FDA is streamlining approval processes, potentially accelerating Dexcom's market entry.
  • Global diabetes management market is expected to reach $98.4 billion by 2028.

What critics are saying

  • Increased competition from new health tech wearables like MindMics' earbuds.
  • Regulatory scrutiny and data privacy concerns may slow GenAI adoption.
  • Stelo sensors may face challenges in market adoption due to existing competition.

What makes Dexcom unique

  • Dexcom's G6 CGM System offers real-time glucose monitoring for diabetes management.
  • Stelo is the first GenAI-enabled CGM, providing personalized health insights.
  • Dexcom's partnership with Google enhances AI capabilities in glucose biosensing.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$51.3M

Below

Industry Average

Funded Over

6 Rounds

Post IPO Convertible funding comparison data is currently unavailable. We're working to provide this information soon!
Post IPO Convertible Funding Comparison
Coming Soon

Benefits

Health Insurance

Professional Development Budget

Remote Work Options

Flexible Work Hours

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

0%
Stock Titan
Feb 27th, 2025
Dexcom Announces Upcoming Conference Presentation

Dexcom (NASDAQ:DXCM) has announced its upcoming participation in the 46th Annual Raymond James Institutional Investors Conference.

MarketBeat
Feb 23rd, 2025
Fisher Funds Management LTD Invests $96.51 Million in DexCom, Inc. (NASDAQ:DXCM)

Fisher Funds Management LTD invests $96.51 million in DexCom, Inc. (NASDAQ:DXCM).

ETF Daily News
Jan 17th, 2025
Capital Investment Advisors LLC Invests $206,000 in DexCom, Inc. (NASDAQ:DXCM)

Capital Investment Advisors LLC invests $206,000 in DexCom, Inc. (NASDAQ:DXCM).

MedTech Dive
Jan 15th, 2025
Dexcom CEO talks Stelo sensor launch, OTC strategy

Dexcom launched its Stelo sensors last summer to offer an over-the-counter glucose monitor for people with Type 2 diabetes who don't take insulin.

South China Morning Post
Jan 12th, 2025
New health tech wearables at CES measure blood sugar, capture heart murmurs

MindMics' earbuds and DexCom's Stelo patches stand out at CES 2025, while an expert calls the approval process for such devices 'pathetic'

Recently Posted Jobs

Sign up to get curated job recommendations

Dexcom is Hiring for 147 Jobs on Simplify!

Find jobs on Simplify and start your career today

💡
We update Dexcom's jobs every few hours, so check again soon! Browse all jobs →